Mechanism Overview: Melatonin as a Follicle Hormone
Melatonin (N-acetyl-5-methoxytryptamine) is best known as the “sleep hormone” produced by the pineal gland in response to darkness, but it has a much broader role as a tissue-protective molecule with potent antioxidant, anti-inflammatory, and anagen-promoting properties. The hair follicle expresses both MT1 and MT2 melatonin receptors, and local melatonin production has been documented in the outer root sheath and dermal papilla, suggesting that melatonin functions as an autocrine/paracrine hormone within the follicle. The discovery that topical melatonin may promote hair growth has opened a new area of research that extends well beyond melatonin’s well-known effects on sleep.
The dual role of melatonin—as both a systemic hormone and a local follicle-signaling molecule—has important implications for treatment. Systemic melatonin supplementation (oral) has not been shown to benefit hair growth, but topical melatonin applied directly to the scalp has shown positive results in several clinical studies, likely because it achieves high local concentrations at the follicle level.
Detailed Mechanism: Melatonin Receptor Signaling in the Hair Follicle
Melatonin signals through two G-protein coupled receptors: MT1 (also called MTNR1A) and MT2 (MTNR1B). Both receptors are expressed in the human hair follicle, with MT1 being the predominant isoform. Upon melatonin binding, MT1 and MT2 activate Gi proteins that inhibit adenylate cyclase, reducing intracellular cAMP levels—opposite to the effect of caffeine, which increases cAMP through PDE inhibition.
The reduction in cAMP mediated by melatonin receptors has several downstream effects in the hair follicle. First, reduced cAMP levels decrease the activity of protein kinase A (PKA), which can modulate the phosphorylation of transcription factors involved in hair cycle regulation. Second, melatonin receptor activation can activate the ERK1/2 (MAPK) pathway through β-arrestin signaling, promoting cell proliferation and survival in dermal papilla cells and matrix keratinocytes. A study by Kobayashi et al. (2005), published in the Journal of Investigative Dermatology, demonstrated that melatonin stimulated hair growth in vitro through ERK activation, and that this effect was blocked by a melatonin receptor antagonist.
Melatonin also modulates estrogen receptor signaling in the hair follicle. MT1 receptors have been shown to physically interact with ERα, modulating estrogen’s effects on follicle cycling. This interaction may explain why melatonin appears to be more effective for female pattern hair loss than male pattern hair loss in clinical studies.
Detailed Mechanism: Antioxidant and Anti-Inflammatory Effects
Beyond receptor-mediated effects, melatonin is one of the most potent antioxidants identified, with several unique properties. Unlike conventional antioxidants (vitamin C, vitamin E) that typically neutralize one free radical per molecule, melatonin can neutralize up to 10 reactive oxygen and nitrogen species through a cascade of increasingly stable metabolites (6-hydroxymelatonin, N1-acetyl-N2-formyl-5-methoxykynuramine, N1-acetyl-5-methoxykynuramine). This “free radical scavenging cascade” makes melatonin significantly more efficient than other antioxidants on a molar basis.
Melatonin also upregulates the expression of endogenous antioxidant enzymes, including glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT), through activation of the Nrf2 transcription factor. This dual mechanism—direct scavenging plus enzyme induction—provides comprehensive antioxidant protection that is particularly relevant to the hair follicle, where high mitochondrial activity generates significant ROS during anagen.
The anti-inflammatory effects of melatonin include suppression of NF-κB signaling, which reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in follicular cells. This anti-inflammatory effect may help reduce the perifollicular microinflammation documented in androgenetic alopecia, as discussed in our article on the inflammatory cascade in hair loss.
Research Evidence: Clinical Studies on Topical Melatonin
The most important clinical study is by Fischer et al. (2004), published in the British Journal of Dermatology. This randomized, placebo-controlled trial examined topical 0.1% melatonin solution applied once daily for 6 months in 40 women with diffuse hair loss or female pattern hair loss. The melatonin group showed a statistically significant increase in hair count (mean +13.4%) compared to baseline, while the placebo group showed a decrease (mean -3.2%). The effect was seen in both the vertex and temporal regions.
A larger observational study by Fischer et al. (2012), published in the Journal of Plastic Dermatology, examined topical melatonin in 1,891 patients (both men and women) with various forms of hair loss over 30-90 days. The study reported improvement in hair status in 61% of women and 43% of men, with the best results seen in women with diffuse hair loss. However, this was an open-label study without a control group, limiting the strength of the conclusions.
A study by Bhatt et al. (2018) examined the combination of topical melatonin with 5% minoxidil in men with AGA and found that the combination produced better results than minoxidil alone, suggesting an additive effect. However, this study was small (30 patients) and has not been replicated.
Limitations and Evidence Gaps
Several important limitations must be acknowledged. First, the Fischer et al. (2004) study, while positive, was small (40 patients) and has not been independently replicated in a large, well-designed RCT. Second, the mechanism by which topical melatonin promotes hair growth is not fully understood—it may involve receptor-mediated effects, antioxidant effects, anti-inflammatory effects, or a combination. Third, the optimal concentration and formulation for topical melatonin are not established—the Fischer study used 0.1%, but higher concentrations have not been systematically evaluated.
Fourth, oral melatonin supplementation has not been shown to improve hair growth, likely because systemic melatonin levels do not translate to sufficient follicular concentrations. Fifth, melatonin can affect sleep architecture and circadian rhythms when taken orally, and topical melatonin may have minor systemic absorption—though the doses used topically are typically low enough to avoid significant systemic effects.
Frequently Asked Questions
Can I use melatonin for my hair? Topical melatonin (0.1% solution applied once daily, preferably in the evening) has shown positive results in one RCT and one large observational study. It is generally safe and may be worth trying as an adjunct to proven treatments.
Does taking melatonin pills help hair growth? No. Oral melatonin has not been shown to improve hair growth. The effective route appears to be topical application directly to the scalp.
When should I apply topical melatonin? Evening application is recommended because melatonin is naturally produced at night and the evening application aligns with the circadian rhythm of the hair follicle (discussed in our article on circadian rhythms and hair).
Conclusion
Melatonin is a unique molecule with receptor-mediated, antioxidant, and anti-inflammatory effects that are relevant to hair follicle biology. MT1 and MT2 receptors are expressed in the follicle, and melatonin promotes anagen through ERK activation and possibly through modulation of estrogen receptor signaling. The antioxidant cascade makes melatonin one of the most efficient free radical scavengers known, and its anti-inflammatory effects may help reduce perifollicular microinflammation. Clinical evidence from the Fischer et al. (2004) RCT supports the use of topical 0.1% melatonin for female hair loss, with a mean 13.4% increase in hair count over 6 months. However, larger confirmatory trials are needed, and oral melatonin supplementation does not appear to benefit hair growth. Topical melatonin may be a reasonable adjunct to proven treatments, but it should not replace minoxidil or finasteride.